Latest polycystic kidney disease Stories
A drug therapy shows promise for treating an inherited form of kidney disease called autosomal dominant polycystic kidney disease (ADPKD).
Scientists at UC Santa Barbara have demonstrated in the laboratory that a new drug is effective in treating a very common kidney disease –– although it will be a few years before it becomes available for clinical testing.
Loyola University Medical Center researchers are reporting one of the first studies to examine how patients and families are soliciting living kidney donors on Facebook.
About one-third of CT examinations performed following an inconclusive abdominal ultrasound examination have positive findings, according to a study of 449 patients at Massachusetts General Hospital in Boston.
After a four-week course of the vasodilator hormone relaxin, kidney function and blood flow immediately improved in lab rats genetically altered to model polycystic kidney disease (PKD), a life-threatening genetic disorder.
Babies born with autosomal recessive polycystic kidney disease (ARPKD) often develop kidney failure because they have very large kidneys filled with tiny cysts.
The most common kidney disease passed down through families, autosomal dominant polycystic kidney disease (ADPKD) affects one in 400 to 1,000 individuals and is characterized by cysts on the kidneys.
- a slit in a tire to drain away surface water and improve traction.